Market Cap$14.33B
P/E—
PEG Ratio0.12
Div yield—
Beta1.37
CRL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)57.49%
Price vs S&P 500 (4W)8.90%
PEG Ratio0.12
VGM Score44.80
CRL Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $2.74 | $3.02 | +10.31%(+$0.28) | |
| Q1 2026 | $1.95 | $2.06 | +5.42%(+$0.11) | |
| Q4 2025 | $2.35 | $2.39 | +1.91%(+$0.04) | |
| Q3 2025 | $2.34 | $2.43 | +3.86%(+$0.09) | |
| Q2 2025 | $2.55 | $3.12 | +22.45%(+$0.57) |
CRL Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.96
3.96
3.91
4.00
Industry Peers — R&D — Physical Sciences(17)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|---|---|---|
CRLCharles River Laboratories International, Inc. | F | D | A | — | -7.7% | 6.5% | — | $300.15 |
| IQVIQVIA Holdings Inc. | D | C | A | 32.3x | 21.9% | 7.5% | — | $266.90 |
| INCYIncyte Genomics Inc | C | B | B | 17.8x | 29.6% | 14.0% | — | $113.07 |
| MEDPMedpace Holdings, Inc. Common Stock | F | B | B | 38.3x | 110.2% | 22.3% | — | $618.47 |
| ICLRIcon Plc | C | C | B | 57.3x | 0.8% | 24.1% | — | $170.18 |
| ABSIAbsci Corporation Common Stock | F | F | B | — | -59.2% | -10.1% | — | $8.25 |
| OABIOmniAb, Inc. Common Stock | F | B | A | — | -16.6% | -4.3% | — | $4.59 |
| NRCNRC Health Common Stock | D | D | B | 38.4x | 48.5% | 0.6% | 1.2% | $20.15 |
| MXCTMaxCyte, Inc. Common Stock | C | D | B | — | -21.0% | 4.8% | — | $1.30 |
| IBACIB Acquisition Corp. Common Stock | — | D | C | 15.9x | -3.7% | — | — | $10.86 |
| ONMDOneMedNet Corp Class A Common Stock | D | A | D | — | -6.8% | — | — | $4.51 |
About Charles River Laboratories International, Inc.
Charles River Laboratories is a leading provider of drug discovery and development services, operating since 1947. The company's three core segments—research models (supplying genetically characterized animal models for preclinical testing), discovery and safety assessment (early-stage drug development services), and manufacturing support (microbial solutions, in vitro testing, and biologics services)—position it as a critical partner throughout the pharmaceutical development lifecycle.